期刊文献+

大肠癌MDR_(-1)与p53表达关系及其意义 被引量:2

RELATIONSHIP AND SIGNIFICANCE BETWEEN MDR -1 AND p53 PROTEIN IN LARGE INTESTINAL CARCINOMA
下载PDF
导出
摘要 目的探讨大肠癌中多药耐药基因MDR1与p53表达之间的关系。方法利用免疫组化研究60例大肠癌及20例大肠腺瘤MDR-1,p53的表达。结果显示60例大肠癌切片中MDR-1与p53的阳性表达率为57%和37%,10例正常大肠组织和20例大肠腺瘤仅20%显示MDR-1阳性表达,p53在正常大肠组织,管状腺瘤中全部阴性,仅一例有不典型增生的绒毛状腺瘤为阳性表达。同时显示p53在不同分化的大肠癌中与MDR表达呈正相关。结论1)通过检测DMR-1可以对大肠癌病人进行化疗敏感性预测。2)p53过度表达对MDR-1基因可能具有诱导和增加效应。3)p53和MDR-1一起可用作判断病人预后,生物学行为的一个有用参数。 PURPOSE To investigate the relationship between multidrug resistance gene and p53 protein in large intestinal carcinoma.METHODS Microwave immunohistochemical staining was used to detect MDR -1 and p53 in 60 cases of large intestinal carcinoma and 20 cases of adenoma.RESULTS The positive rate of MDR -1 and p53 was 57% and 37% respectively in 60 carcinomas,while in 10 normal large intestinal tissue and 20 adenomas,only 20% were positive for MDR -1 . All the tubular adenomas were negative and only one villous adenoma dysplasia was positive for p53.The expression of p53 was positively correlated with MDR -1 in various differentiated large intestinal carcinoma.CONCLUSION 1)Overexpression of p53 protein might have inducing and increasing effects on MDR -1 gene expression.2) MDR -1 provides us a useful marker to predict chemotherapy sensitivity.3)p53 combined with MDR -1 can be an important parameter in prediction of the prognosis and biological behavior of large intestinal carcinoma patients.
出处 《中国癌症杂志》 CAS CSCD 1999年第1期47-48,共2页 China Oncology
关键词 大肠癌 免疫组化 多药耐药基因 P53基因表达 Large intestinal carcinoma Immunohistochemical staining Multidrug resistance gene p53
  • 相关文献

参考文献1

  • 1高振强 高志萍.多药耐药基因研究进展[J].中华病理学杂志,1992,255:459-459. 被引量:1

同被引文献20

  • 1[1]Lam V, McPherson JP, Salmena L, et al. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leuk Res, 1999,23: 871-880. 被引量:1
  • 2[4]Nakata B, Chung KH, Ogawa M, et al. p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer. Surg Today, 1998, 28:595-598. 被引量:1
  • 3[7]Lebedeva I, Rando R, Ojwang J, et al. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res, 2000, 60: 6052-6060. 被引量:1
  • 4[8]Luo D, Cheng SC, Xie H, et al. Effects of Bcl-2 and Bcl-xL protein levels on chemoresistance of hepatoblastoma HepG2 cell line.Biochem Cell Biol, 2000, 78: 119-126. 被引量:1
  • 5[11]Amundson SA, Myers TG, Scudiero D, et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res, 2000, 60: 6101-6110. 被引量:1
  • 6[12]Lincet H, Poulain L, Remy JS, et al. The p21 (cipl/wafl) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett, 2000,161: 17-26. 被引量:1
  • 7[13]Marks DI, Kurz BW, Link MP, et al. Altered expression of p53and mdm 2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J Clin Oncol,1997,15:1158-1162. 被引量:1
  • 8[15]Lenz HJ, Hayashi K, Salonga D, et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res, 1998, 4: 1243-1250. 被引量:1
  • 9[16]Makris A, Powles TJ, Dowsett M, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res, 1997, 3:593-600. 被引量:1
  • 10[22]Staunton JE, Slonim DK, Coller HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA,2001, 98: 10787-10792. 被引量:1

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部